Fondaparinux vs Lepirudin in the treatment of heparin-induced thrombocytopenia, with or without thrombosis. A multicenter, randomized, parallel group study of treatment with fondaparinux (7.5 mg s.c. once daily) versus aPTT-adjusted Lepirudin infusion (0,15 or 0,10 mg/Kg/hr) in the management of patients with heparin-induced thrombocytopenia with or without thrombosis.

Trial Profile

Fondaparinux vs Lepirudin in the treatment of heparin-induced thrombocytopenia, with or without thrombosis. A multicenter, randomized, parallel group study of treatment with fondaparinux (7.5 mg s.c. once daily) versus aPTT-adjusted Lepirudin infusion (0,15 or 0,10 mg/Kg/hr) in the management of patients with heparin-induced thrombocytopenia with or without thrombosis.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 07 Mar 2013

At a glance

  • Drugs Fondaparinux sodium (Primary) ; Lepirudin
  • Indications Embolism and thrombosis; Heparin-induced thrombocytopenia and thrombosis syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms FLHIT
  • Most Recent Events

    • 28 Apr 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
    • 11 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top